Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02867709 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,686
- Enrollment target
NCT02867709 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 1,686 participants.
The verdict
NCT02867709, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,686 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
Interventions
- DRUG Ubrogepant
- DRUG Placebo-matching Ubrogepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,686 participants |
| Start Date | 2016-08-26 |
| Est. Completion | 2018-02-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02867709
The ClinicalTrials.gov registry entry for NCT02867709 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,686 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ubrogepant is the first listed.
NCT02867709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02867709 about?
NCT02867709 is a clinical study titled "Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine". This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
What is the current status of trial NCT02867709?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,686 participants. The study started on 2016-08-26. Estimated completion is 2018-02-26.
What interventions are being tested in trial NCT02867709?
The interventions under investigation include: Ubrogepant (DRUG), Placebo-matching Ubrogepant (DRUG).
Who is sponsoring clinical trial NCT02867709?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.